-
Uncategorized2 months ago
Novel KIR‑CAR T Approach Shows Early Activity Against Solid Tumors
CAR T cell therapies have revolutionized outcomes for certain blood cancers, yet their impact on solid tumors has lagged. The field has long wrestled with T...
-
Uncategorized2 months ago
BBOT shakes up leadership as RAS competitors get more visibility
Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes a busy period of clinical advancement in...
-
Uncategorized2 months agoThe next generation of cancer therapies revealed at AACR 2026
The American Association for Cancer Research (AACR) Annual Meeting 2026 took place 17-22 April 2026. Here we share some of the themes discussed and key data...
-
Uncategorized2 months ago
Novo’s pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud
Novo's pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud
-
Uncategorized2 months ago
Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change
Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s patents had anything to do with the departure...
-
Uncategorized2 months agoSTAT+: AMA calls for regulatory crackdown on chatbots, wellness AI
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your...
-
Uncategorized2 months ago
Endpoints wins Neal Awards for Trump and gene editing coverage, JPM event
Endpoints wins Neal Awards for Trump and gene editing coverage, JPM event
-
Uncategorized2 months agoAcross 7 hearings, RFK Jr. talks a new, more moderate MAHA
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning, we made it to Thursday. Thanks...
-
Uncategorized2 months ago
Unnamed pharma files citizen petition targeting FDA’s trove of rejection letters
The FDA in July 2025 made publicly available over 200 complete response letters—an initiative that the investment community sees as “unanimously positive,” analysts told BioSpace.
-
Uncategorized2 months ago
Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’
Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks—falling far below analyst and investor...
Hantavirus One-Shot mRNA Vaccine Fully Protects in Syrian Hamster Model
SonoThera Raises $125M to Develop Ultrasound-Mediated Genetic Medicines
